Senaste nyheterna

31 Maj 2023 13:26

AstraZeneca övergår till exklusiv användning av Cision för pressmeddelandeutskick

Från och med den 1 juni kommer AstraZeneca att upphöra med att skicka ut pressmeddelanden från Mynewsdesk. I stället kommer Cision att användas exklusivt som kanal för pressmeddelandeutskick.

26 Maj 2023 08:06

Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD)

Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.

26 Maj 2023 08:01

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in...

25 Maj 2023 08:01

AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023

AstraZeneca advances its ambition to revolutionise cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2 to 6 June 2023.

17 Maj 2023 08:02

Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

Positive high-level results from the FLAURA2 Phase III trial showed Tagrisso in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated non-small cell lung cancer.

16 Maj 2023 08:02

AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023

AstraZeneca will present new clinical and real-world data in multiple haematological conditions, further demonstrating its ambition to redefine care in haematology at the European Hematology Association (EHA) 2023 Hybrid Congress, 8 to 11 June 2023.

10 Maj 2023 08:01

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

Ultomiris (ravulizumab) has been approved in the European Union (EU) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).

Kontakter

Karl-Johan Karlsson

Presskontakt Tf presschef, AstraZeneca AB karl-johan.karlsson@astrazeneca.com +46735801268

Mathias Holm Pedersen

Presskontakt Kommunikationschef, AstraZeneca Nordic mathias.pedersen@astrazeneca.com +45 22937730